🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05453240
Enrolling by invitation Observational

Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the LVIS Device

NCT05453240 · tracked via the Priya Life Science USA tracker
Sponsor
Microvention-Terumo, Inc.
Phase
Observational
Started
2020-11-17
Last updated
2025-06-17

Condition(s) studied

Intracranial Aneurysms

Study summary

The proposed study is a multi-center single arm retrospective and prospective data collection, of patients treated with the LVIS device of specific sizes of 3.5mm, 4.0mm, 4.5mm, 5.5mm with up to 5 years follow-up. Information collected during the study will be standardized across centers to include pre-treatment baseline characteristics of patients including aneurysm(s) symptoms, procedural information, prespecified clinical safety events of interest, and follow-up imaging, clinical visits or telephone calls.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: The following criteria match the FDA-approved indications for use per PMA (P170013) * Subjects treated with the LVIS® Device in accordance with currently approved indications for use; * Treatment of wide-necked (neck ≥ 4mm or dome to neck ratio \< 2) intracranial saccular aneurysm arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 4.5 mm who underwent treatment with LVIS device of researched sizes within the last 5 years. (Device models: 212517-LVIS, 212525-LVIS, 213015-LVIS, 213025-LVIS, 213041-LVIS, 214035-LVIS, 214049-LVIS; 212912-LVIS, 212917-LVIS, 212922-LVIS, 212928-LVIS, and 212931-LVIS); * Availability of Medical Health Records; * Subject whose age is ≥ 18; * Appropriate or Waived Consent: 1. For retrospective review: Local Institutional Review Board approves the research as exempt, allowing an all-inclusive retrospective examination of medical records documenting treatments using the study devices and available clinical and imaging follow up; 2. For prospective follow up: Subject or his/her Legally Authorized Representative consents to participation in the study follow up visits up to 5 years, and provides a signed informed consent form as applicable;. Exclusion Criteria: * Subjects not treated according to the currently approved indications for use

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Microvention Aliso Viejo California

More Microvention-Terumo, Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05453240 on ClinicalTrials.gov ↗ ← All trials in the USA